Results 61 to 70 of about 34,807 (281)
The pharmacogenetics of methotrexate [PDF]
Rheumatology, 2007 Methotrexate (MTX) is a cornerstone of therapy for rheumatoid arthritis. However, it is not universally effective and up to one-third of patients fail to respond to treatment, either because of inefficacy or adverse events, although at present it is not possible to predict therapy response accurately.
S L, Hider, I N, Bruce, W, Thomson
openaire +2 more sources
British Journal of Clinical Pharmacology, EarlyView.Introduction Warfarin therapy is the mainstay of anticoagulation treatment in South Africa and requires frequent INR monitoring due to interindividual patient variability. Time in therapeutic range (TTR) reflects the proportion of total treatment time during which INR values are within therapeutic range.
Masudah Paleker +3 more
wiley +1 more source
Current status quo on Pharmacogenetics in psychiatry
, 2022 BACKGROUND: Medication side effects and limited efficacy are substantial problems in general and also in psychopharmaceuticals. Previous studies have shown that pharmacogenetic individual characteristics can be relevant.
Birkenhäger, Tom K. +1 more
core +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Safe prescribing and effective medication review during acute hospitalization depends on accurate information about liver and kidney function because these organs are responsible for the elimination of most medications. While estimates for kidney function are widely used, comparable markers of hepatic drug‐metabolizing capacity are not routinely ...
Louise Westberg Strejby Christensen +17 more
wiley +1 more source
Atypical functions of xenobiotic receptors in lipid and glucose metabolism
Medical Review, 2022 Xenobiotic receptors are traditionally defined as xenobiotic chemical-sensing receptors, the activation of which transcriptionally regulates the expression of enzymes and transporters involved in the metabolism and disposition of xenobiotics.
Wang Jingyuan, Lu Peipei, Xie Wen
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.Improvement in medication adherence is often proposed as a potential advantage of pharmacogenetic‐guided prescribing over a traditional one‐size‐fits‐all approach. This paper provides a review of the published literature and presents the findings of studies that measure adherence to medication as an outcome of pharmacogenetic‐informed care, or that ...
Lucy Galloway +2 more
wiley +1 more source
Gabapentin as an add‐on analgesic to morphine in paediatric patients with chronic pain
British Journal of Clinical Pharmacology, EarlyView.Aims Off‐label use of gabapentin for the treatment of chronic pain in children has increased over the last decade, with multiple clinical trials evaluating its role pain management and potential opioid‐sparing effects. To date, however, these studies appear to rely on empirical evidence without further consideration of pharmacokinetic‐pharmacodynamic ...
Paul Healy +15 more
wiley +1 more source
Pharmacogenetics of Sult1A1 [PDF]
Pharmacogenomics, 2014 Cytosolic SULT1A1 participates in the bioconversion of a plethora of endogenous and xenobiotic substances. Genetic variation in this important enzyme such as SNPs can vary by ethnicity and have functional consequences on its activity. Most SULT1A1 genetic variability studies have been centered on the SULT1A1*1/2 SNP.
Jaclyn, Daniels, Susan, Kadlubar
openaire +2 more sources
CYP3A5 genetic variability influences sildenafil and metabolite in pulmonary hypertension
British Journal of Clinical Pharmacology, EarlyView.Aim Interindividual variability in sildenafil response among pulmonary hypertension patients (PH) may be influenced by CYP3A5 polymorphisms. CYP3A5*3 allele reduces CYP3A5 activity and affects sildenafil metabolism. This study investigated the associations between CYP3A5 genotype and plasma concentrations of sildenafil and N‐desmethyl sildenafil, as ...
Pranisa Wongwien +7 more
wiley +1 more source